{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:21:26Z","timestamp":1787498486558,"version":"build-2736575974"},"reference-count":119,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T00:00:00Z","timestamp":1276732800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["PM&amp;R"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.pmrj.2010.03.011","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T04:46:26Z","timestamp":1276836386000},"page":"544-558","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Strategies to Optimize Pain Management With Opioids While Minimizing Risk of Abuse"],"prefix":"10.1002","volume":"2","author":[{"given":"Michael J.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Stanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,17]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.12.003"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181671c5a"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.05.005"},{"key":"e_1_2_8_5_2","first-page":"1","article-title":"Opioid guidelines in the management of chronic non\u2010cancer pain","volume":"9","author":"Trescot A.M.","year":"2006","journal-title":"Pain Physician"},{"key":"e_1_2_8_6_2","first-page":"S5","article-title":"Opioids in the management of chronic non\u2010cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP Guidelines)","volume":"11","author":"Trescot A.M.","year":"2008","journal-title":"Pain Physician"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318125c5e8"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/AJP.0b013e31814b1d46","article-title":"Opioid use and abuse: Is there a problem?","volume":"23","author":"Gagnon A.M.","year":"2007","journal-title":"Clin J Pain"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.3.249"},{"key":"e_1_2_8_10_2","first-page":"16313","article-title":"Identification of Drug and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration Amendments Act of 2007. Docket No. FDA\u20102008\u2010N0174","volume":"73","author":"US Department of Health and Human Services","year":"2008","journal-title":"Federal Register"},{"key":"e_1_2_8_11_2","unstructured":"Chronic Pain in America: Roadblocks to Relief; a study conducted by Roper Starch Worldwide for American Academy of Pain Medicine American Pain Society and Janssen Pharmaceutica.January 1999"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210953.86255.8f"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2008.00223.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31818164f2"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-006-0084-1"},{"key":"e_1_2_8_16_2","first-page":"23","article-title":"Use of opioids","volume":"56","author":"Stanos S.","year":"2007","journal-title":"J Fam Pract"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.4.489"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00017"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.007"},{"key":"e_1_2_8_20_2","unstructured":"IMS NPA Rx Monthly.IMS Health Web sitehttp:\/\/www.imshealth.com Accessed September 23 2009"},{"key":"e_1_2_8_21_2","unstructured":"Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H\u201034 DHHS Publication No. SMA 08\u20104343). Rockville MD."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210915.80417.cf"},{"key":"e_1_2_8_23_2","volume-title":"Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady","author":"Johnston L.D.","year":"2008"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00255.x"},{"key":"e_1_2_8_25_2","unstructured":"Substance Abuse and Mental Health Services Administration Office of Applied Studies (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings (NSDUH Series H\u201032 DHHS Publication No. SMA 07\u20104293). Rockville MD."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0013636"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00603.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550880802122570"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0013634"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.12.013"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.02.432"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-6-46"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1452"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00006"},{"key":"e_1_2_8_35_2","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.36076\/ppj.2008\/11\/S63","article-title":"Therapeutic opioids: A ten year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids","volume":"11","author":"Manchikanti L.","year":"2008","journal-title":"Pain Physician"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00370.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0013628"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.18.2370"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200207001-00004"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.793"},{"key":"e_1_2_8_41_2","unstructured":"Under the counter: the diversion and abuse of controlled prescription drugs in the US. The National Center on Addiction and Substance Abuse at Columbia University 2005"},{"key":"e_1_2_8_42_2","first-page":"101","article-title":"Experiences of patients requiring strong opioid drugs for chronic non\u2010cancer pain: A patient\u2010initiated study","volume":"57","author":"Blake S.","year":"2007","journal-title":"Br J Gen Pract"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2005.11.6.469"},{"key":"e_1_2_8_44_2","first-page":"287","article-title":"Prescription drug abuse: What is being done to address this new drug epidemic?. Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources","volume":"9","author":"Manchikanti L.","year":"2006","journal-title":"Pain Physician"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2006.08.004"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.00072.x"},{"key":"e_1_2_8_49_2","first-page":"135","article-title":"Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice","volume":"94","author":"Brown R.L.","year":"1995","journal-title":"Wis Med J"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1155\/1996\/391248"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00119-6"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2003.03038.x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4637.2003.03017.x"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.07.026"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.03.010"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.10.009"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2006.00067.x"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.01.014"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.11.014"},{"key":"e_1_2_8_60_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpainsymman.2007.11.006","article-title":"Introduction of a self\u2010report version of the Prescription Drug Use Questionnaire and relationship to medication agreement compliance","volume":"336","author":"Compton P.A.","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00110-9"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199706000-00009"},{"key":"e_1_2_8_63_2","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.36076\/ppj.2008\/11\/S155","article-title":"Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility","volume":"11","author":"Manchikanti L.","year":"2008","journal-title":"Pain Physician"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.04.007"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31816b1070"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90057-4"},{"key":"e_1_2_8_67_2","first-page":"1","article-title":"Screening for opioid abuse potential","volume":"16","author":"Passik S.D.","year":"2008","journal-title":"Pain"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.05.010"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.03.001"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(82)90005-3"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_2_8_72_2","author":"Washington State Agency Medical Directors' Group","journal-title":"Interagency Guideline on Opioid dosing for chronic non\u2010cancer pain: An educational pilot to improve care and safety with opioid treatment. Agency Medical Directors Group"},{"key":"e_1_2_8_73_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.36076\/ppj.2004\/7\/333","article-title":"Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain","volume":"7","author":"Atluri S.L.","year":"2004","journal-title":"Pain Physician"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.05031.x"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31817e13cc"},{"key":"e_1_2_8_76_2","first-page":"301","article-title":"Rational use and interpretation of urine drug testing in chronic opioid therapy","volume":"37","author":"Reisfield G.M.","year":"2007","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2007.06.001"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00354.x"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(02)01800-8"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/81.1.58"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.007"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31816b2f26"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.03.015"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31802b582f"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2008.00233.x"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65321"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2007\/10\/399"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/J354v19n01_05"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00254.x"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00399.x"},{"key":"e_1_2_8_91_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1081\/JA-100106227","article-title":"Blancing diversion control and medical necessity: The case of prescription drugs with abuse potential","volume":"36","author":"Simoni\u2010Wastila L.","year":"2001","journal-title":"Substance Abuse Misuse"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.802"},{"issue":"1","key":"e_1_2_8_93_2","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","article-title":"Development of opioid formulations with limited diversion and abuse potential","volume":"83","author":"Fudala P.J.","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"e_1_2_8_94_2","doi-asserted-by":"crossref","unstructured":"S.F.Butler S.H.Budman A.Licari T.A.Cassidy K.Lioy J.Dickinson et al.National addictions vigilance intervention and prevention program (NAVIPPRO\u2010TM: A real\u2010time product\u2010specific. public health surveillance system for monitoring prescription drug abusePharmacol Drug Safety.2008[In press]","DOI":"10.1002\/pds.1659"},{"key":"e_1_2_8_95_2","author":"Paulozzi L.J.","journal-title":"Trends in unintentional drug overdose deaths. Testimony before Senate Judiciary Committee on Crime and Drugs"},{"key":"e_1_2_8_96_2","unstructured":"TheraQuest Biosciences.Our product candidateshttp:\/\/www.theraquestinc.com\/pipeline\/products.htm2006 Accessed February 20 2009"},{"key":"e_1_2_8_97_2","unstructured":"TheraQuest Biosciences.Ultram\u2010ER extended\u2010release tablets 2008http:\/\/www.theraquest.com Accessed February 20 2009"},{"key":"e_1_2_8_98_2","unstructured":"TheraQuest Biosciences 2009http:\/\/www.theraquest.com Accessed February 20 2009."},{"key":"e_1_2_8_99_2","unstructured":"TheraQuest Biosciences.TheraQuest's IND for abuse deterrent strong opioid (TQ\u20101015) accepted by FDA November 13 2008http:\/\/www.theraquestinc.com\/news\/pressrelease\/pr_08_11_13.htm Accessed February 23 2009"},{"key":"e_1_2_8_100_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2146\/news080018","article-title":"Abuse deterrence focus of upcoming opioid formulations","volume":"65","author":"Lavine G.","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2179"},{"key":"e_1_2_8_102_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.3.359"},{"key":"e_1_2_8_103_2","unstructured":"Pain Therapeutics' Remoxy\u2122cleared for US Clinical trials. Pain Therapeutics Inc. September 2 2004. Available online at:http:\/\/investor.paintrials.com\/releasedetail.cfm?ReleaseID=297384. Accessed September 23 2009."},{"key":"e_1_2_8_104_2","unstructured":"IntelliPharmaCeutics announces successful completion of a pilot clinical trial for its abuse and alcohol resistant sustained release oxycodone. IntelliPharmaCeutics Ltd. March 27 2008. Available online at:http:\/\/www.intellipharmaceutics.com\/contact\/news_2008_march_27.htm. Accessed August 7 2009."},{"key":"e_1_2_8_105_2","unstructured":"Akela Pharmaceuticals Inc.Akela Pharmaceuticals initiates its first abuse deterrent opioid phase I clinical trial March 6 2008http:\/\/www.akelapharma.com\/modules.php?op=modload&name=News&file=article&sid=67 Accessed September 23 2009"},{"key":"e_1_2_8_106_2","unstructured":"Collegium Pharmaceutical Inc.Collegium Pharmaceutical Inc. announces FDA acceptance of IND for its abuse deterrent sustained release opioid product July 12 2007http:\/\/www.collegiumpharma.com\/news\/20070712.html Accessed September 24 2009"},{"key":"e_1_2_8_107_2","unstructured":"Collegium Pharmaceutical Inc.Collegium Pharmaceutical Inc. announces submission of a request for special protocol assessment to FDA for pivotal trial for tamper resistant extended release opioid (COL\u2010003)[press release]. June 10 2009http:\/\/www.businesswire.com\/portal\/site\/home\/permalink\/?ndmViewId=news_view&newsId=20090610005046&newsLang=en"},{"key":"e_1_2_8_108_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253861"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-7-3"},{"key":"e_1_2_8_110_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902751622"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00672.x"},{"key":"e_1_2_8_112_2","unstructured":"Neuromed Pharmaceuticals Inc. Neuromed announces Exalgo (hydromorphone HCl) extended\u2010release tablet [press release].PharmaLive.comnews archive. March 23 2009."},{"key":"e_1_2_8_113_2","unstructured":"CombintoRx Incorporated and Neuromed Pharmaceuticals Inc. FDA extends NDA review for Exalgo extended\u2010release tablets [press release].PharmaLive.comnews archive. November 20 2009."},{"key":"e_1_2_8_114_2","unstructured":"Innovators in pain management.Egalet a\/shttp:\/\/www.egalet.com Accessed January 11 2010"},{"key":"e_1_2_8_115_2","unstructured":"Egalet a\/s. Effects of a single dose of Egalet\u00ae. morphine combined with a single dose of alcohol in healthy moderate drinkers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000\u2010[January 11 2010]. Available online at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00802308NLM Identifier: NCT00802308."},{"key":"e_1_2_8_116_2","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jpain.2009.01.154","article-title":"Egalet\u00ae morphine, a once\u2010a\u2010day abuse resistant opioid analgesic: A.double\u2010blind, randomized, cross\u2010over efficacy study in cancer patients","volume":"10","author":"Andersen C.","year":"2009","journal-title":"J Pain"},{"key":"e_1_2_8_117_2","unstructured":"Egalet a\/s. Single dose pharmacokinetics of Egalet\u00ae oxycodone. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000\u2010[January 11 2010]. Available online at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00801788NLM Identifier: NCT00801788."},{"key":"e_1_2_8_118_2","unstructured":"Egalet a\/s. Single dose pharmacokinetics of Egalet\u00ae hydrocodone. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000\u2010[January 11 2010]. Available online at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00802087NLM Identifier: NCT00802087."},{"key":"e_1_2_8_119_2","unstructured":"Embeda [package insert]. Bristol TN: King Pharmaceuticals\u00ae Inc.; June 2009."},{"key":"e_1_2_8_120_2","first-page":"155","article-title":"Meeting background material","author":"Purdue Pharma L.P.","year":"2008","journal-title":"Joint meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)"}],"container-title":["PM&amp;R"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.pmrj.2010.03.011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934148210002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934148210002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.pmrj.2010.03.011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T16:29:28Z","timestamp":1694708968000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.pmrj.2010.03.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1016\/j.pmrj.2010.03.011"],"URL":"https:\/\/doi.org\/10.1016\/j.pmrj.2010.03.011","archive":["Portico"],"relation":{},"ISSN":["1934-1482","1934-1563"],"issn-type":[{"value":"1934-1482","type":"print"},{"value":"1934-1563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"2009-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}